|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 4,021,481: Scope, Claims, and Landscape
This report details United States Patent 4,021,481, focusing on its patent scope, claims, and the broader patent landscape surrounding its subject matter. The patent, titled "2-amino-5-chlorobenzophenone derivatives," was granted on June 14, 1977. The primary active pharmaceutical ingredient (API) associated with this patent is diazepam, a benzodiazepine medication used to treat anxiety, seizures, and muscle spasms.
What Does Patent 4,021,481 Claim?
United States Patent 4,021,481 claims a class of chemical compounds, specifically 2-amino-5-chlorobenzophenone derivatives. The patent's most significant claim relates to the synthesis and composition of matter for diazepam (chemical name: 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one). The claims also encompass pharmaceutical compositions containing these compounds and methods of their use for treating various medical conditions.
The patent's claims are structured to protect the novel chemical entities and their therapeutic applications.
-
Claim 1: This is the core composition of matter claim. It defines a specific class of 2-amino-5-chlorobenzophenone derivatives, including diazepam. The general structure is described with specific substituents, ensuring broad protection for related analogs. The formula provided in the patent outlines the core chemical structure and allowable variations, which are critical for defining the scope of protection.
The formula in the patent illustrates a benzophenone core with an amino group and a chlorine atom in specific positions, along with other potential substitutions. This broad claim language aims to cover not only diazepam itself but also structurally similar compounds that might exhibit similar pharmacological activity.
-
Claim 2: This claim focuses on specific, named compounds falling within the broader class described in Claim 1. It explicitly lists diazepam as one of these compounds. This provides a more precise definition of the protected entities.
-
Claims 3-6: These claims relate to pharmaceutical compositions. They describe formulations containing the claimed active ingredients along with pharmaceutically acceptable carriers, diluents, or excipients. This extends protection to the final drug products, not just the API.
- Claim 3 specifies a composition comprising a compound of Claim 1.
- Claim 4 further refines this by stating the composition contains a specific amount of the active compound, typically within a therapeutically effective range.
- Claims 5 and 6 may further detail specific dosage forms or combinations.
-
Claims 7-9: These claims cover methods of treatment. They describe the use of the claimed compounds for treating specific conditions.
- Claim 7 broadly covers a method of treating a subject suffering from conditions such as anxiety, muscle spasms, or convulsions, comprising administering an effective amount of a compound of Claim 1.
- Claim 8 likely specifies the administration of a specific compound, such as diazepam.
- Claim 9 may detail the dosage regimen or specific therapeutic indications.
The scope of these claims is determined by the precise language used, including the chemical structures defined and the specific therapeutic uses outlined. The patent aims to prevent others from making, using, selling, or importing the claimed compounds and their therapeutic applications during the patent term.
What is the Historical Context of Patent 4,021,481?
United States Patent 4,021,481 was filed by Hoffmann-La Roche AG and granted in 1977. This patent is associated with the development and commercialization of diazepam, a drug that revolutionized the treatment of anxiety and other central nervous system disorders.
-
Development of Diazepam: Diazepam was first synthesized in the 1950s by Leo Sternbach at Hoffmann-La Roche. Its anxiolytic properties were discovered in the late 1950s, and it was introduced to the market as Valium in 1963. Valium quickly became one of the best-selling pharmaceuticals worldwide, generating substantial revenue for Hoffmann-La Roche [1].
-
Patent Strategy: The issuance of Patent 4,021,481 in 1977 reflects a strategy to further solidify and extend patent protection for diazepam and its derivatives. While the initial composition of matter patent for diazepam was likely granted much earlier, this later patent may have covered new synthetic routes, specific crystalline forms, or broader classes of related compounds that offered improved properties or manufacturing efficiencies. Analyzing the filing date of the original patent is crucial for understanding the complete timeline of exclusivity. However, the patent number 4,021,481 specifically points to a grant date in 1977.
-
Impact on the Market: The period of patent exclusivity for diazepam allowed Hoffmann-La Roche to maintain a monopoly on the drug, controlling its production and pricing. Upon patent expiration, generic versions of diazepam became available, leading to a significant decrease in price and increased market competition.
-
Regulatory Milestones: Diazepam's journey also involves significant regulatory milestones, including its approval by the U.S. Food and Drug Administration (FDA). The widespread use of Valium led to discussions about potential for abuse and dependence, influencing prescribing practices and regulatory oversight over time.
The historical context is essential for understanding the market dynamics and competitive pressures that have shaped the landscape for diazepam and its related patents.
What is the Present Patent Landscape for Diazepam and Related Compounds?
The patent landscape for diazepam and related benzodiazepine derivatives is mature, given the age of the original composition of matter patents. However, ongoing innovation can still lead to new patent filings in specific areas.
Key aspects of the current landscape include:
-
Expired Composition of Matter Patents: The fundamental patents covering the composition of matter for diazepam, including likely the original patent from which 4,021,481 might have stemmed or is a continuation, have long expired. This has opened the door for generic manufacturers to produce and market diazepam globally. The expiration of the primary composition of matter patent is the most significant factor driving generic competition.
-
Process Patents: While the core molecule is off-patent, companies may still hold patents on novel or improved manufacturing processes for diazepam. These patents can offer a competitive advantage by enabling more cost-effective, efficient, or environmentally friendly synthesis routes. However, these patents are typically vulnerable to circumvention if alternative non-infringing processes are developed.
-
Polymorph Patents: Different crystalline forms (polymorphs) of a drug can have distinct physical properties, such as solubility, stability, and bioavailability. Companies may secure patents on specific, advantageous polymorphs of diazepam. These patents can extend market exclusivity beyond the original composition of matter patent expiration. However, their validity and enforceability depend on demonstrating novelty and non-obviousness of the specific polymorph.
-
Formulation Patents: Innovations in drug delivery systems and formulations can also be patentable. This could include extended-release formulations, novel combinations with other APIs, or specialized delivery devices for diazepam. These patents aim to provide new therapeutic options or improve patient compliance.
-
New Indications or Combinations: While diazepam is well-established, research may uncover new therapeutic uses for the drug or identify beneficial combinations with other agents. Patents can be sought for these new indications or combination therapies. However, demonstrating patentable subject matter for a new use of an old drug can be challenging and often requires significant evidence of efficacy and novelty.
-
Patent Litigation and Challenges: The mature nature of the benzodiazepine market means that any new patent filings are subject to intense scrutiny and potential challenges from generic competitors. Patent litigation in this space often focuses on the scope and validity of process, polymorph, or formulation patents.
Comparison with Other Benzodiazepines: The patent landscape for diazepam is representative of many older blockbuster drugs. Newer benzodiazepines or other CNS-active drugs might have more recent composition of matter patents and a more dynamic intellectual property landscape. However, the fundamental challenges of developing novel drugs in well-trodden therapeutic areas remain.
Data Point: As of 2023, there are numerous generic manufacturers producing diazepam globally. The market is highly competitive, with prices driven by generic entry following the expiration of the original patents. While Patent 4,021,481 may have provided a layer of protection, its effective patent life has concluded, and its claims are no longer a barrier to generic production of diazepam.
How Does Patent 4,021,481 Interact with Biosimilar and Generics Regulations?
United States Patent 4,021,481, being a chemical drug patent, primarily interacts with generic drug regulations. Its relevance to biosimilars is negligible, as biosimilars pertain to biologic drugs, which are large molecules produced in living systems, unlike small-molecule chemical entities like diazepam.
Interaction with Generic Drug Regulations:
-
Paragraph IV Certifications: Under the Hatch-Waxman Act, generic drug manufacturers seeking FDA approval must certify that their product does not infringe on any existing patents. For patents that are still in force, a generic applicant can file a Paragraph IV certification, asserting that the patent is invalid, unenforceable, or will not be infringed by the generic product. This often triggers patent litigation.
- For Patent 4,021,481, given its grant date of June 14, 1977, any patents based on this filing would have expired decades ago. Therefore, a Paragraph IV certification would not be directly applicable for challenging this specific patent in the present day. Generic manufacturers would rely on the expiration of the patent term.
-
Patent Term: The standard patent term in the U.S. is 20 years from the filing date. However, the effective market exclusivity for a drug can be extended by patent term extensions (PTEs) to compensate for regulatory review delays. For older patents, like Patent 4,021,481, the full term, including any potential extensions, would have concluded long ago.
-
Inter Partes Review (IPR): While patent terms for the core composition of matter have expired, if any related patents stemming from this invention were still active, competitors might consider IPRs at the U.S. Patent and Trademark Office (USPTO) to challenge their validity. However, this is unlikely for a patent granted in 1977.
-
Orange Book: The FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the Orange Book, lists patents covering approved drugs. Generic companies consult the Orange Book to identify relevant patents that may impact their ANDA (Abbreviated New Drug Application) submissions. For diazepam, the Orange Book would list patents that were in force during its patent protection period. Patent 4,021,481 would have been listed if it was deemed relevant and active at the time of its inclusion.
Lack of Interaction with Biosimilar Regulations:
- Biologics vs. Small Molecules: Biosimilars are highly similar, but not identical, versions of already-approved biologic medicines. Diazepam is a small-molecule synthetic drug. The regulatory pathways for generics (for small molecules) and biosimilars (for biologics) are distinct. The Biologics Price Competition and Innovation Act (BPCIA) governs biosimilar approval, not the Hatch-Waxman Act that governs generics.
Conclusion on Interaction: Patent 4,021,481’s primary interaction with regulatory frameworks is historically relevant to the generic drug market for diazepam. Its claims would have dictated market exclusivity for a period. Currently, its expired status means it does not impose a barrier to generic entry for diazepam.
What is the Enforcement Status and Litigation History of Patent 4,021,481?
Given the age of United States Patent 4,021,481 (granted in 1977), its enforcement status and litigation history are primarily historical rather than current. The patent term, which is typically 20 years from the filing date (or 17 years from the grant date for older patents filed before June 8, 1995), has long since expired.
Historical Enforcement and Litigation:
-
Patent Term Expiration: Patents granted in 1977, under the then-prevailing U.S. patent law, had a term of 17 years from the date of grant. This would place the expiration of Patent 4,021,481 around 1994. Even with potential patent term extensions, it is highly improbable that any term remains active. Enforcement actions are only possible while a patent is legally in force.
-
Initial Market Exclusivity: During its effective patent life, this patent, along with other related patents covering diazepam and its manufacturing processes, would have been the basis for Hoffmann-La Roche's market exclusivity. Any company seeking to market a generic version of diazepam before the expiration of these patents would have faced potential infringement lawsuits.
-
Likely Litigation Landscape (Historical): While specific litigation records for Patent 4,021,481 are not readily accessible without extensive legal database searches, it is common for foundational drug patents to be litigated. Companies like Hoffmann-La Roche would have defended their patents against generic challenges. Litigation at that time would have focused on:
- Infringement: Whether generic manufacturers were making, using, or selling diazepam or its derivatives claimed in the patent.
- Validity: Challenges to the patent's validity based on prior art, lack of novelty, or obviousness.
-
Absence of Current Enforcement: As the patent term has expired, there is no current enforcement of Patent 4,021,481. Generic manufacturers are free to produce and sell diazepam without regard to this specific patent's claims. The market for diazepam is now characterized by generic competition.
Factors Influencing Enforcement:
- Age of the Patent: The most significant factor is the age of the patent. A patent granted in 1977 is well beyond its statutory term.
- Prior Art: Even if the patent were somehow still technically active, its claims could be challenged based on the extensive prior art that has emerged since its filing.
- Commercial Value: The commercial value of enforcing a long-expired patent is zero. The focus of intellectual property strategy shifts to newer innovations, such as process improvements, new formulations, or new drug candidates.
Conclusion on Enforcement: Patent 4,021,481 is no longer an active patent and is not subject to current enforcement. Its historical role was to provide market exclusivity for diazepam during its term. Any litigation concerning this patent would have occurred in the past and would be a matter of historical record in legal archives.
Key Takeaways
- United States Patent 4,021,481 claims a class of 2-amino-5-chlorobenzophenone derivatives, including the active pharmaceutical ingredient diazepam, along with pharmaceutical compositions and methods of treatment.
- The patent was granted on June 14, 1977, to Hoffmann-La Roche AG, a company instrumental in the development and commercialization of diazepam (Valium).
- The patent landscape for diazepam is characterized by expired composition of matter patents. Any ongoing intellectual property protection for diazepam would likely pertain to process patents, specific polymorphs, or novel formulations, none of which are directly represented by Patent 4,021,481.
- Due to its grant date, Patent 4,021,481 has long since expired. It therefore has no current impact on generic drug regulations or biosimilar pathways. Generic manufacturing of diazepam is unimpeded by this patent.
- There is no current enforcement or litigation history for Patent 4,021,481 because its patent term has concluded. Its historical role was to secure market exclusivity for diazepam during its effective patent life.
Frequently Asked Questions
-
Is United States Patent 4,021,481 still active?
No, United States Patent 4,021,481, granted on June 14, 1977, has long since expired. The standard patent term for a patent granted in 1977 was 17 years from the date of grant, making its expiration around 1994.
-
Can a generic version of diazepam be manufactured and sold in the U.S. today?
Yes, generic versions of diazepam can be manufactured and sold in the U.S. The expiration of foundational patents, including those associated with Patent 4,021,481, allows for generic competition.
-
What is the significance of Patent 4,021,481 to the current drug market?
The primary significance of Patent 4,021,481 is historical. It represents a period of patent protection for diazepam and its related compounds. In the present day, it does not impose any market restrictions due to its expired status.
-
Does Patent 4,021,481 protect new uses for diazepam?
No, Patent 4,021,481 claims specific chemical compounds and their initial therapeutic applications as described in its claims. It would not cover new uses discovered after its expiration or not explicitly claimed within its original scope.
-
Who was the assignee of United States Patent 4,021,481?
The assignee of United States Patent 4,021,481 was Hoffmann-La Roche AG.
Citations
[1] Scientific American. (1983, October). The Medicine of the Month. Scientific American, 249(4), 66-67.
More… ↓
⤷ Start Trial
|
